EOS006215
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EOS006215, covering 2025-08-12 to 2025-08-12. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors [Phase 1]